Siren L.L.C. Sells 2,974,053 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Siren L.L.C. lowered its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 73.8% in the 1st quarter, HoldingsChannel reports. The fund owned 1,053,464 shares of the company’s stock after selling 2,974,053 shares during the period. Centessa Pharmaceuticals accounts for approximately 1.2% of Siren L.L.C.’s holdings, making the stock its 23rd largest holding. Siren L.L.C.’s holdings in Centessa Pharmaceuticals were worth $41,844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares during the period. Wells Fargo & Company MN increased its position in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at approximately $100,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $40.50 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $12.74 and a 52-week high of $40.56. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The firm has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. The stock has a 50 day moving average price of $40.12 and a 200 day moving average price of $33.64.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on CNTA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $35.00 to $42.00 in a research note on Monday, April 20th. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their price target for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.